Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Intesity Therapeutics Inc INTS

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.


NDAQ:INTS - Post by User

User Avatar Image
(1384)
•••
  • IseneschalX
Post by Iseneschalon Oct 30, 2025 2:16pm
28 Views
Post# 36768679

INTS....don't Drink the Kool-Aide

INTS....don't Drink the Kool-AideYou'll be sorry !!!!!!
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities